Adaptive Biotechnologies to Present 2 Studies Demonstrating Utility of Immunosequencing to Propel Diagnostic Development and Therapeutic Discovery at the 2016 American Association of Immunologists Annual Meeting
Saturday, May 14, 2016
SEATTLE, Wa., May 14, 2015 – Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, will present data demonstrating how profiling the T-cell repertoire has the potential to advance diagnostic development and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in Seattle, May 13-17, 2016.
“As evidenced by these data, assessing the presence of associated T-cell responses can serve as a powerful diagnostic classifier in infectious diseases,” says Dr. Harlan Robins, Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies. “We are also continuing to expand our proprietary immunosequencing technology into a highly useful tool for therapeutic discovery, changing the paradigm of treatment for infectious diseases, autoimmunity and cancer.”
Adaptive is also hosting an exhibitor workshop at AAI on Sunday, May 15, 1:45-2:30 p.m. Exhibitor Workshop Room 2, featuring Catherine Sanders, PhD from Adaptive Biotechnologies, to discuss how utilizing immunosequencing can accelerate innovation and discovery.
Representatives from Adaptive Biotechnologies will be exhibiting at AAI booth #446 to answer questions about its immunosequencing technology.
Oral Presentations:
Abstract #209.04: A scalable multiplex assay enabling assessment of T cell receptor specificity to hundreds of self- and pathogen-derived antigens
Tuesday, May 17, 2016, 11:00-11:15 a.m.
Room 611-612
Presenter: Mark Klinger, Adaptive Biotechnologies
Poster Presentations:
Abstract #148.11 - Immunosequencing reveals diagnostic signatures of pathogen infection and HLA type in the T-cell Receptor Repertoire
Sunday, May 15, 2016, 2:30-3:45 p.m.
Poster# 2777, Poster Hall
Presenter: Will DeWitt, Adaptive Biotechnologies
Abstract #209.04: A scalable multiplex assay enabling assessment of T cell receptor specificity to hundreds of self- and pathogen-derived antigens
Monday, May 16, 2016, 2:30-3:45 p.m.
Poster# 2232, Poster Hall
Presenter: Mark Klinger, Adaptive Biotechnologies
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.
CONTACT:
Adaptive Biotechnologies
April Falcone
206-939-3835
media@adaptivebiotech.com
As evidenced by these data, assessing the presence of associated T-cell responses can serve as a powerful diagnostic classifier in infectious diseases.